Cytochroma Not Capital Deficient

January 18 2007

Cytochroma, a Markham, Ontario-based drug company focused on diseases and disorders related to vitamin D deficiency, has raised Cnd$21 million in third-round funding. Backers include The VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund. www.cytochroma.com

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Nearly there!

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.